Navigation Links
IMD Announces 35% Increase in Revenues for OMI
Date:8/2/2011

TAMPA, Fla., Aug. 2, 2011 /PRNewswire/ -- IMD Companies Inc. announces that when it files its Second Quarter Financial Reports with OTC Markets, LLC, the reports will reflect a 35% increase in revenues for Integrated Medical Diagnostics (Integrated) and Optimum Mobile Imaging (OMI) bringing the year to date revenues of the subsidiaries to $149,839. Both Integrated and OMI are wholly owned subsidiaries that were purchased by IMD last year to operate the company's diagnostic testing business.  Testing operations continue to be performed in several states with OMI mainly concentrated in Arizona, but the companies are working on expanding testing into new markets in the near future.  The primary service offered by Integrated is the PCI Heartscan®, which concentrates on the early detection of Cardio Vascular disease and describes blockage in the carotid arteries, while OMI provides mobile imaging services in several modalities to the medical community. The company will file its complete financial reports this month.

"As promised in our open letter to shareholders, the company continues to expand operations and achieve revenue growth in its diagnostic testing arena," stated IMD CEO Saeb Jannoun. "We have been able to create this growth in testing while remaining focused on expansion into the disease prevention and weight-loss industries," Jannoun concluded.  Earlier this year IMD announced the acquisition of Positive Solutions Centers, LLC. as a subsidiary to develop and grow their juvenile weight-loss business.

ABOUT IMD COMPANIES, INC.

IMD Companies, Inc., (OTC MARKETS: ICBU) is a Florida corporation, engaged in the medical diagnostics and health and fitness industries. Its primary products and services lie in the health and fitness nutraceutical and medical diagnostics services markets. The company further plans to expand into the weight-loss industry.

The company delivers its medical diagnostic services on-site participating medical clinics and physician offices. The nutraceutical supplements, pills, bar and gels will be marketed and distributed through participating clinics and on-line web marketing retail methods.  The company will continue to develop its innovative marketing strategies, including the use of social networking vehicles.


Safe Harbor Statement:

Certain statements made in this press release constitute forward-looking statements that are based on management's expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. All forward-looking statements speak only as of the date of this press release and the company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

www.imdcompanies.com


'/>"/>
SOURCE IMD Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Adolfson & Peterson Construction (AP) ... Ramsey County Medical Examiners Facility located in Saint Paul, Minn. A single story, ... scheduled to start in late 2017/early 2018. , Staffed by 20 full-time ...
(Date:7/21/2017)... ... July 21, 2017 , ... Bernard R. Bach, Jr., MD, orthopaedic ... American Orthopaedic Society of Sports Medicine (AOSSM) , received the 2017 Robert E. ... Meeting in Toronto, Canada. This prestigious award is given annually to honor those who ...
(Date:7/21/2017)... ... 21, 2017 , ... MedMatchPlus+ has launched a residency application ... a residency in a United States hospital. Being accepted into a residency is ... to data released by the ECFMG®, every year, 50 percent of international medical ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients ... decade after surgery, though activity levels decline over time. The study, presented today ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ChenMed ... MD, has joined JenCare Senior Medical Center as Richmond Chief Medical Officer. ... School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA ...
Breaking Medicine News(10 mins):